Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec Expands Collaboration with MedImmune

Published: Monday, January 07, 2013
Last Updated: Monday, January 07, 2013
Bookmark and Share
Evotec AG has expanded the scope of its collaboration with MedImmune after hitting a key milestone. Evotec achieved a milestone payment of €0.5 m.

The milestone triggers a commercial license granted to MedImmune and an extension of the diabetes and beta cell regeneration collaboration to the end of 2013.

This license and collaboration agreement in the diabetes therapeutic area was initiated in December 2010. Within the agreement MedImmune has exclusive access to a defined set of biologic targets that have the potential to prevent or reverse disease progression in diabetic patients. The size of the combined research team has expanded and Evotec will receive additional research payments to support in vitro and in vivo experiments.

As part of the original agreement, Evotec received an upfront payment of €5 m and could earn up to €254 m in further milestones and payments as well as royalties on product sales. The majority of milestone payments are due upon achievement of certain clinical as well as regulatory and commercial milestones.  Further milestone payments may be achieved with the approval of additional indications and programs.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “Together with our colleagues at MedImmune and AstraZeneca we have been highly productive in driving forward the development of EVT770 as well as additional molecules in the portfolio. We are proud that we have already achieved the second milestone in this collaboration and are very much looking forward to expanding our efforts and thereby laying the foundation for continued success.”

Dr Cristina Rondinone, Vice President and Head of MedImmune’s Cardiovascular and Metabolic Disease Center of Excellence, said: “We are excited to expand our collaboration with Evotec. Diabetes has reached epidemic levels and it is one of the biggest causes of mortality worldwide. Therefore, it is critical that we develop novel and highly effective therapies to slow down and ultimately stop the development of diabetes.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec Awarded Contract to Manage NCI CBC Screening Libraries Center
Company will provide compound management services for a period of five years.
Friday, October 09, 2015
Evotec Enters into Agreement with Pfizer
Licence and collaboration agreement in the field of tissue fibrosis.
Friday, September 11, 2015
Evotec and Sanofi Enter into Exclusive Negotiations
Goal to improve innovation effectiveness in drug discovery and pre-clinical development.
Thursday, December 04, 2014
Evotec Receives Milestone Payment as part of its Discovery Alliance with Boehringer Ingelheim
Company receives milestone payment of € 1.0 m.
Thursday, June 19, 2014
Evotec to Establish an Anti-infectives Platform with the Acquisition of Euprotec Ltd
Adds key know-how and infectious disease therapeutic area capabilities.
Thursday, May 29, 2014
Evotec Acquires UK-Based CRO Euprotec
Company announce the acquisition of all shares in Euprotec Ltd, a recognised leader in anti-infective drug discovery services
Thursday, May 29, 2014
Evotec Acquires Bionamics to Accelerate 'EVT Innovate' Strategy
Expanding discovery pipeline with portfolio of projects especially in Multiple Sclerosis and CNS.
Saturday, March 29, 2014
Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim
The milestone relates to the transition of an oncology molecule into pre-clinical development.
Tuesday, December 10, 2013
Evotec Achieves First Milestones in Multi-target Deal with UCB
Projects move into hit-to-lead and lead optimization.
Thursday, October 31, 2013
Evotec raises € 30 m from Biotechnology Value Fund
Biotechnology Value Fund, L.P. and other affiliates of US investment firm BVF partners L.P. (“BVF”) invest € 30 M in new Evotec shares.
Monday, September 02, 2013
Evotec Enters Biology Collaboration with Probiodrug
Evotec will setup and validate assays to support the pre-clinical and clinical development of QC inhibitors in Alzheimer’s disease.
Thursday, November 29, 2012
Evotec Extends Ongoing Collaboration with CHDI Foundation
Collaboration aims to accelerate development of drugs that slow the progression of Huntington's disease.
Monday, November 05, 2012
Evotec and Aspireo Enter into Strategic Advisory Agreement
Teaming up to partner Aspireo’s Somatoprim (DG3173).
Wednesday, October 03, 2012
Evotec and Bayer Enter into Multi-target Alliance to Fight Endometriosis
Companies have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis.
Monday, October 01, 2012
Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
Company receives milestone payment of EUR 2.5 million.
Thursday, September 27, 2012
Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!